Aztreonam–Avibactam for Patients Who are Critically Ill with Gram-Negative Bacterial Infections: Comparison with Colistin Plus Meropenem Subgroup from the Phase 3 REVISIT Study

INTRODUCTION: The phase 3 REVISIT trial evaluated aztreonam-avibactam versus meropenem ± colistin for complicated intra-abdominal infection (cIAI), hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP). This descriptive post hoc analysis explored efficacy and safety of aztreonam-avibactam versus colistin plus meropenem in patients with cIAI or HAP/VAP. METHODS: This post hoc analysis included patients who received colistin plus meropenem (all with baseline Acute Physiology and Chronic Health Evaluation II [APACHE II] scores ≥ 8) and patients who received aztreonam-avibactam with baseline APACHE II scores ≥ 8, for comparable baseline severity. The primary efficacy endpoint was adjudicated clinical cure rate at the test-of-cure (TOC) visit in the intent-to-treat (ITT) and clinically evaluable (CE) analysis sets. Secondary endpoints included clinical cure rate at TOC by infection type, favorable microbiological response at TOC, 28-day mortality, and safety. Efficacy and safety outcomes were compared descriptively. RESULTS: Overall, we included 186 patients in the ITT population (aztreonam-avibactam, n = 160; colistin plus meropenem, n = 26). Clinical cure rates (95% CI) were 63.1% (55.5-70.3) and 53.8% (35.1-71.8) for aztreonam-avibactam and colistin plus meropenem, respectively (ITT). Results were similar in the CE analysis set. Clinical cure rates in both cIAI and HAP/VAP subgroups were consistent with the overall results, although 95% CIs were wide and the number of patients treated with colistin plus meropenem was small. Microbiological response rate was 71.7% for aztreonam-avibactam and 46.7% for colistin plus meropenem (microbiological ITT). Twenty-eight-day mortality was similar for aztreonam-avibactam (7.5%) and colistin plus meropenem (11.5%; ITT). Proportions of patients with all-cause adverse events (AEs) and serious AEs were generally similar in both groups, with fewer treatment-related AEs for aztreonam-avibactam. CONCLUSIONS: This exploratory post hoc analysis provides further insights into the efficacy and safety of aztreonam-avibactam versus colistin plus meropenem in patients with cIAI or HAP/VAP who were critically ill. CLINICAL TRIAL REGISTRATION: NCT number: NCT03329092.

Authors

Institutions

Publication Details

Journal
Infectious Diseases and Therapy
Published
2026-11-12
DOI
https://doi.org/10.1007/s40121-026-01477-3
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Aztreonam–Avibactam for Patients Who are Critically Ill with Gram-Negative Bacterial Infections: Comparison with Colistin Plus Meropenem Subgroup from the Phase 3 REVISIT Study

Naglaa Mohamed, José Miguel Cisneros, Yongjie Zhao, 许进福 et al.
Infectious Diseases and Therapy
Antibiotic Resistance in Bacteria
article

Aztreonam–Avibactam for Patients Who are Critically Ill with Gram-Negative Bacterial Infections: Comparison with Colistin Plus Meropenem Subgroup from the Phase 3 REVISIT Study

Naglaa Mohamed, José Miguel Cisneros, Yongjie Zhao, 许进福, Heidi K. Leister-Tebbe, Yehuda Carmeli, Minggui Wang, George L. Daikos, Joanne Louise Leaney, Jinyi Yuan, Shweta Kamat, Michele Wible, Mical Paul, Wenjuan Xu, Ying Ma
article en

Abstract

INTRODUCTION: The phase 3 REVISIT trial evaluated aztreonam-avibactam versus meropenem ± colistin for complicated intra-abdominal infection (cIAI), hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP). This descriptive post hoc analysis explored efficacy and safety of aztreonam-avibactam versus colistin plus meropenem in patients with cIAI or HAP/VAP. METHODS: This post hoc analysis included patients who received colistin plus meropenem (all with baseline Acute Physiology and Chronic Health Evaluation II [APACHE II] scores ≥ 8) and patients who received aztreonam-avibactam with baseline APACHE II scores ≥ 8, for comparable baseline severity. The primary efficacy endpoint was adjudicated clinical cure rate at the test-of-cure (TOC) visit in the intent-to-treat (ITT) and clinically evaluable (CE) analysis sets. Secondary endpoints included clinical cure rate at TOC by infection type, favorable microbiological response at TOC, 28-day mortality, and safety. Efficacy and safety outcomes were compared descriptively. RESULTS: Overall, we included 186 patients in the ITT population (aztreonam-avibactam, n = 160; colistin plus meropenem, n = 26). Clinical cure rates (95% CI) were 63.1% (55.5-70.3) and 53.8% (35.1-71.8) for aztreonam-avibactam and colistin plus meropenem, respectively (ITT). Results were similar in the CE analysis set. Clinical cure rates in both cIAI and HAP/VAP subgroups were consistent with the overall results, although 95% CIs were wide and the number of patients treated with colistin plus meropenem was small. Microbiological response rate was 71.7% for aztreonam-avibactam and 46.7% for colistin plus meropenem (microbiological ITT). Twenty-eight-day mortality was similar for aztreonam-avibactam (7.5%) and colistin plus meropenem (11.5%; ITT). Proportions of patients with all-cause adverse events (AEs) and serious AEs were generally similar in both groups, with fewer treatment-related AEs for aztreonam-avibactam. CONCLUSIONS: This exploratory post hoc analysis provides further insights into the efficacy and safety of aztreonam-avibactam versus colistin plus meropenem in patients with cIAI or HAP/VAP who were critically ill. CLINICAL TRIAL REGISTRATION: NCT number: NCT03329092.

Infectious Diseases and Therapy
Technion – Israel Institute of Technology (IL), Pfizer (United States) (US), Pfizer (United Kingdom) (GB), National and Kapodistrian University of Athens (GR), Fudan University (CN), Tel Aviv Sourasky Medical Center (IL), Rambam Health Care Campus (IL), Shanghai Pulmonary Hospital (CN), Instituto de Biomedicina de Sevilla (ES), Pfizer (China) (CN), Hospital Universitario Virgen del Rocío (ES), Huashan Hospital (CN), Pfizer (India) (IN)
U.S. Department of Health and Human Services, Pfizer, European Federation of Pharmaceutical Industries and Associations, European Commission, Biomedical Advanced Research and Development Authority
Good health and well-being
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon